[在慢性髓性白血病治疗中使用尼洛尼布治疗后可逆性脑病综合征]
Daisuke Kudo1, Hiroshi Suzuki1, Naomi Abe1
1Department of Hematology, Tokyo-Kita Medical Center.
[Rinsho ketsueki] The Japanese journal of clinical hematology
|January 14, 2024
概括
尼罗丁尼是慢性髓性白血病的治疗方法,可能会导致后置逆脑病综合征 (PRES). 这种罕见的不良事件涉及高血压和神经症状,但在停止服用药物后会消失.
科学领域:
- 在瘤学瘤学.
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 慢性髓性白血病 (CML) 是一种骨髓增殖性瘤.
- 尼罗丁尼是一种用于CML治疗的氨酸激酶抑制剂.
- 氨酸激酶抑制剂可以产生各种不良影响.
研究的目的:
- 报告与尼洛尼治疗相关的第一个后置可逆脑病综合征 (PRES) 病例.
- 为了突出尼洛尼在CML患者的潜在严重不良事件.
主要方法:
- 一个50岁的女性患有CML,接受尼洛丁尼治疗的病例报告.
- 描述了临床表现,PRES的诊断和治疗方法.
- 对类似不良事件的潜在机制和现有文献的审查.
主要成果:
- 患者患有PRES,症状包括头痛,视力模糊,意识受损和严重高血压.
- 尼洛丁尼的治疗被停止,患者接受了抗高血压治疗和呼吸机支持.
- 在尼洛尼布停用后,神经和高血压症状迅速消失.
结论:
- 尼罗丁尼可能会导致PRES,一种严重的血管不良事件.
- 该机制可能涉及尼罗丁尼诱导的高血压和影响血脑屏障的内皮功能障碍.
- 这一案例强调了在用尼洛尼治疗的CML患者中对PRES的监测的重要性.
更多相关视频
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.4K
11:29HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
Published on: July 20, 2016
11.1K
相关概念视频
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
163
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
163
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
167
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
167